Literature DB >> 2444960

Failure of conventional chemotherapy in aggressive lymphomas.

D Cunningham1, A Hepplestone, N L Gilchrist, J H Dagg, I L Evans, M Soukop.   

Abstract

Between 1975 and 1982 in 2 centres in Glasgow, 53 previously untreated patients with aggressive non-Hodgkin's lymphomas received chemotherapy consisting of one of the following regimens-CVP, MOPP, CHOP or BACOP. Twenty nine patients (55%) entered complete remission (CR), 20 (38%) had partial remission (PR) and 4 (7%) had progressive disease (PD). Of the 29 patients in CR, 9 have relapsed and died, 5 died of infection, 4 died of non-malignant causes, and 11 (21%) remain alive and disease free. The median survival for the CR group is 40 months. All of the patients in the PR and PD group are dead, median survival 11 months. These chemotherapy regimens will cure only the minority of patients with aggressive lymphomas and the use of more intensive regimens is indicated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444960      PMCID: PMC2428198          DOI: 10.1136/pgmj.63.735.11

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  9 in total

1.  Immunologic characterization of human malignant lymphomas.

Authors:  R J Lukes; R D Collins
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

2.  Successful therapy of convoluted T-lymphoblastic lymphoma in the adult.

Authors:  A M Levine; S J Forman; P R Meyer; S C Koehler; H Liebman; A Paganini-Hill; A Pockros; R J Lukes; D I Feinstein
Journal:  Blood       Date:  1983-01       Impact factor: 22.113

3.  Advanced diffuse histiocytic lymphoma, a potentially curable disease.

Authors:  V T DeVita; G P Canellos; B Chabner; P Schein; S P Hubbard; R C Young
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

4.  Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.

Authors:  R I Fisher; V T DeVita; S M Hubbard; D L Longo; R Wesley; B A Chabner; R C Young
Journal:  Ann Intern Med       Date:  1983-03       Impact factor: 25.391

5.  Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.

Authors:  J Laurence; M Coleman; S L Allen; R T Silver; M Pasmantier
Journal:  Ann Intern Med       Date:  1982-08       Impact factor: 25.391

6.  Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).

Authors:  A T Skarin; G P Canellos; D S Rosenthal; D C Case; J M MacIntyre; G S Pinkus; W C Moloney; E Frei
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

7.  The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology.

Authors:  C J Gallagher; A Copplestone; J D Meikle; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study.

Authors:  S E Jones; P N Grozea; E N Metz; A Haut; R L Stephens; F S Morrison; J J Butler; G E Byrne; T E Moon; R Fisher; C L Haskins; C A Coltman
Journal:  Cancer       Date:  1979-02       Impact factor: 6.860

9.  Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP).

Authors:  A T Skarin; D S Rosenthal; W C Moloney; E Frei
Journal:  Blood       Date:  1977-05       Impact factor: 22.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.